![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, October 31, 2006 9:57:16 AM
October 31, 2006
8:56AM Lumera: Harvard Medical School researchers to build next generation discovery and diagnostics methods with co's
ProteomicProcessor Biosensor (LMRA) 6.35 : Co announces that Harvard Medical School researchers are now building next generation discovery and diagnostics methods with it's ProteomicProcessor Biosensor. During the past year, Lumera has placed four beta units with highly respected, world renowned research organizations to demonstrate and establish new applications that take advantage of the instrument's unprecedented throughput in a label-free format. Harvard has served as a beta site for Lumera's biosensor platform, the ProteomicProcessor(TM), since mid-2006. The Harvard collaboration is focused on integrating their NAPPA (Nucleic Acid Programmable Protein Array) technology, which provides a simple and cost-effective way to generate a protein biochip, with the ProteomicProcessor(TM) to read and analyze the biochip.
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM